Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 dose reduction and maintenance in alopecia areata
NCT04784533Phase 2Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deuruxolitinib in alopecia areata, sponsored by Concert Pharmaceuticals. Started Feb 2021; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04784533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784533.